There are currently 63 active clinical trials seeking participants for Metastatic Cancer research studies. The states with the highest number of trials for Metastatic Cancer participants are California, Ohio, Michigan and Illinois.
FOG-001 in Locally Advanced or Metastatic Solid Tumors
NCT05919264
Recruiting
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2024
Locations: Honor Health, Scottsdale, Arizona +8 locations
Conditions: Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor, Metastatic Cancer, WNT Pathway, β-catenin, Beta-catenin, Adenomatous Polyposis Coli, APC, HCC, Desmoid, Microsatellite Stable Colorectal Cancer, Metastatic Castration-resistant Prostate Cancer, FAP, Endometrial Carcinoma, Prostate Cancer, Microsatellite Instability-High Colorectal Cancer, CTNNB1, Adamantinomatous Craniopharyngioma
Register for Updates
A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
NCT06174987
Recruiting
This open-label, multicenter, rollover study will provide continued treatment for participants deriving benefit from different therapies received in studies sponsored by Daiichi Sankyo, Inc. (DS) or DS/Astra Zeneca (AZ)-sponsored study (eg. DS8201-A-J101, DS8201-A-U201, DS8201-A-U204, DS8201-A-U207, DS8201-A-U303).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/11/2024
Locations: Miami Cancer Institute, Miami, Florida +24 locations
Conditions: Advanced Cancer, Metastatic Cancer
Register for Updates
Niraparib in Tumors Metastatic to the CNS
NCT04992013
Recruiting
This research is being done to see how effective the drug niraparib is against cancer that has metastasized to the central nervous system (CNS). * This research study involves the study drug niraparib.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/09/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts +2 locations
Conditions: Metastatic Cancer, Central Nervous System Cancer
Register for Updates
Comprehensive Outcomes for After Cancer Health
NCT05349227
Recruiting
This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have completed primary therapy for cancer. Up to 625 individuals with diverse cancer diagnoses will be enrolled across up to 8 clinical sites to participate in a randomized wait-list control study. Those in the intervention group will receive 6 months of digital coaching up front followed by 6 months of ongoing monitoring via patient reported and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2024
Locations: The University of Florida, Gainesville, Florida +6 locations
Conditions: Ovarian Cancer, Breast Cancer, Lung Cancer, Gastric Cancer, Survivorship, Endometrial Cancer, Head and Neck Cancers, Prostate Cancers, Geriatric Oncology, Metastatic Breast Cancer, Metastatic Cancer
Register for Updates
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
NCT04657068
Recruiting
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan * Learn more about the side effects of ART0380 alone and in combination with gemcitabine or irinotecan * Learn more about the effectiveness of ART0380 alone and in combination with gemcitabine or irinotecan
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama +43 locations
Conditions: Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Register for Updates
(Peak) a Phase 3 Randomized Trial of CGT9486+Sunitinib Vs. Sunitinib in Subjects with Gastrointestinal Stromal Tumors
NCT05208047
Recruiting
This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll approximately 442 patients. Part 1 consists of two evaluations: 1) confirming the dose of an updated formulation of CGT9486 to be used in subsequent parts in approximately 20 patients who have received at least one prior line of therapy for GIST and 2) evaluating the potential for drug-drug interactions between CGT9486 and sunitinib in approximatel... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama +125 locations
Conditions: Advanced Gastrointestinal Stromal Tumors, Metastatic Cancer
Register for Updates
Molecularly Targeted Theranostic Approach for the Detection and Treatment of Metastatic Carcinomas
NCT06389123
Recruiting
This is a Phase I study to evaluate the safety and efficacy of the \[68Ga\]Ga DOTA-5G and \[177Lu\]Lu DOTA-ABM-5G theranostics pair in patients with metastatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2024
Locations: The University of California Davis Comprehensive Cancer Center, Sacramento, California
Conditions: Metastatic Cancer
Register for Updates
Assessment of Early Radiation Oncology Involvement Alongside Standard Oncologic Care in the Managemet
NCT05351294
Recruiting
To determine if the experimental approach of early radiation oncology involvement alongside standard oncologic care will result in higher HRQL at 6 months compared to the control arm receiving standard oncologic care alone, based on the global subscale score of the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/26/2024
Locations: RWJBarnabas Health Jersey City Medical Center, Jersey City, New Jersey +5 locations
Conditions: Radiation Therapy, Metastatic Cancer
Register for Updates
Evaluating Disparities in Precision Oncology
NCT06081517
Recruiting
This is a non-randomized observational trial designed to collect detailed clinical, social determinant, and genomic data from patients enrolled in molecular oncology tumor boards across four comprehensive cancer centers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/24/2024
Locations: Indiana University Health Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana
Conditions: Metastatic Cancer, Advanced Cancer
Register for Updates
Optimizing Y90 Therapy for Radiation Lobectomy
NCT04390724
Recruiting
HCC resection candidates with inadequate future liver remnant will be enrolled in this study. They will be treated with Y90 radioembolization to help grow the liver enough to undergo liver resection. There will be 2 Patient Groups. The first group of patients will be treated with Y90 dose and embolic load as per standard-of-care. The second group of patients will be treated with the optimal Y90 dose and embolic load found in Patient Group 1.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2024
Locations: Northwestern University, Chicago, Illinois
Conditions: HCC, Resection, Transplant, Metastatic Cancer, Adult Primary Liver Cancer
Register for Updates
Imaging of Solid Tumors Using FAP-2286
NCT04621435
Recruiting
This is a multi-arm prospective trial that evaluates the ability of a novel imaging radiolabeled agents to detect metastatic cancer in participants with solid tumors using a gallium 68 (68Ga-) or copper 64 (64Cu-) FAP-2286 tracer. FAP-2286 is a peptidomimetic molecule that that binds to Fibroblast Activation Protein (FAP). FAP is a transmembrane protein expressed on cancer-associated fibroblasts, and has been shown to be present on a number of solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2024
Locations: University of California, San Francisco, San Francisco, California
Conditions: Solid Tumors, Adult, Metastatic Cancer
Register for Updates
A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors
NCT06190886
Recruiting
The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of PTX-912 in patients with locally advanced or metastatic solid tumors. To evaluate the PK and immunogenicity profile of PTX-912. To evaluate the preliminary anti-tumor activity of PTX-912. Participants will be treated with PTX-912 via iv infusion, every 2 weeks until progression of disease, unacceptable toxicity, or 12 months of total study therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/04/2024
Locations: City of Hope National Medical Center, Duarte, California +2 locations
Conditions: Advanced Cancer, Solid Tumor, Metastatic Cancer
Register for Updates